# Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone

> **NCT02880319** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 150 (actual)

## Conditions studied

- Bone Cancer

## Interventions

- **DRUG:** Stereotactic Body Radiation Therapy (SBRT)
- **DEVICE:** Stereotactic Linear Accelerator

## Key facts

- **NCT ID:** NCT02880319
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11-29
- **Primary completion:** 2022-05
- **Final completion:** 2027-05
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02880319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02880319, "Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02880319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*